https://www.selleckchem.com/pr....oducts/rucaparib.htm
71 times in ACEI users compared with ACEI nonusers. In stratification analysis, both ARB and ACEI both exhibited a protective effect for community-acquired pneumonia in each age and sex group. In the analysis of the effects of therapy duration, patients using ARB for fewer than 100days exhibited a greater reduction in the risk of community-acquired pneumonia (adjusted HR=0.58) compared with the non-ARB cohort. For the ACEI study, patients who used ACEI for 121-450days were more likely to exhibit reduced risks of community-acquired pne
Like
Comment
Share
